Digital Biology with insitro's Daphne Koller

Daphne Koller is the founder and CEO of insitro, a company using AI and machine learning to engineer drug discovery. In this conversation with a16z's Vijay Pande, she discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.
[0:00] Why life sciences?
[3:23] AI in the life sciences
[7:02] LLM for cells
[11:37] Engineering disease and drug discovery
[13:33] Bits vs. atoms
[17:36] The opportunity ahead
This conversation is part of our AI Revolution series, recorded August 2023 at a live event in San Francisco. The series features some of the most impactful builders in the field of AI discussing and debating where we are, where we’re going, and the big open questions in AI. Find more content from our AI Revolution series on www.a16z.com/AIRevolution.

[@breaktherules6035]

EXCELLENT insights! THANK YOU so much for sharing!

[@BrainvsAI]

This is interesting 🤯

[@josephpareti9156]

awesome

[@SuperSnallygaster]

Isn't there a critical element of causality missing, though, with this approach?

[@ab1560]

Cellular systems are far to complex to try to get a complete causal/mechanistic understanding based on the current technology we have.

[@SuperSnallygaster]

@@ab1560 Agreed. I guess that's my point.

[@deneicy]

Voila, Political Modeling.